A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 190,514 shares of IONS stock, worth $6.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
190,514
Previous 249,514 23.65%
Holding current value
$6.87 Million
Previous $11.9 Million 35.83%
% of portfolio
0.01%
Previous 0.02%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$40.06 - $51.86 $2.36 Million - $3.06 Million
-59,000 Reduced 23.65%
190,514 $7.63 Million
Q2 2024

Aug 09, 2024

BUY
$36.45 - $47.7 $2.54 Million - $3.33 Million
69,800 Added 38.84%
249,514 $11.9 Million
Q1 2024

May 13, 2024

BUY
$42.03 - $53.55 $2.83 Million - $3.6 Million
67,300 Added 59.87%
179,714 $7.79 Million
Q4 2023

Feb 13, 2024

SELL
$43.39 - $51.63 $6.83 Million - $8.13 Million
-157,386 Reduced 58.33%
112,414 $5.69 Million
Q3 2023

Nov 14, 2023

SELL
$38.5 - $47.13 $3.88 Million - $4.75 Million
-100,700 Reduced 27.18%
269,800 $12.2 Million
Q2 2023

Aug 11, 2023

SELL
$34.73 - $43.33 $9.23 Million - $11.5 Million
-265,814 Reduced 41.77%
370,500 $15.2 Million
Q1 2023

May 12, 2023

SELL
$33.58 - $41.2 $18.2 Million - $22.4 Million
-542,500 Reduced 46.02%
636,314 $22.7 Million
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $11.5 Million - $14.5 Million
311,100 Added 35.85%
1,178,814 $44.5 Million
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $9.24 Million - $12.3 Million
252,900 Added 41.13%
867,714 $38.4 Million
Q2 2022

Aug 12, 2022

BUY
$31.71 - $43.0 $15.2 Million - $20.6 Million
479,900 Added 355.71%
614,814 $22.8 Million
Q1 2022

May 13, 2022

SELL
$29.88 - $37.04 $2.87 Million - $3.55 Million
-95,900 Reduced 41.55%
134,914 $5 Million
Q4 2021

Feb 11, 2022

BUY
$25.61 - $35.1 $3.41 Million - $4.67 Million
133,100 Added 136.21%
230,814 $7.02 Million
Q3 2021

Nov 12, 2021

SELL
$33.54 - $40.55 $22.8 Million - $27.5 Million
-678,700 Reduced 87.41%
97,714 $3.28 Million
Q2 2021

Aug 13, 2021

BUY
$34.54 - $47.25 $6.53 Million - $8.93 Million
189,000 Added 32.17%
776,414 $31 Million
Q1 2021

May 13, 2021

SELL
$42.51 - $63.78 $6.71 Million - $10.1 Million
-157,934 Reduced 21.19%
587,414 $26.4 Million
Q4 2020

Feb 10, 2021

SELL
$45.3 - $60.27 $32.7 Million - $43.5 Million
-721,819 Reduced 49.2%
745,348 $42.1 Million
Q3 2020

Nov 13, 2020

SELL
$47.45 - $62.95 $13.6 Million - $18 Million
-285,700 Reduced 16.3%
1,467,167 $69.6 Million
Q2 2020

Aug 13, 2020

BUY
$46.85 - $61.05 $3.02 Million - $3.94 Million
64,456 Added 3.82%
1,752,867 $103 Million
Q1 2020

May 14, 2020

SELL
$41.6 - $63.4 $14.6 Million - $22.2 Million
-350,300 Reduced 17.18%
1,688,411 $79.8 Million
Q4 2019

Feb 13, 2020

BUY
$53.85 - $65.27 $12.2 Million - $14.7 Million
225,700 Added 12.45%
2,038,711 $123 Million
Q3 2019

Nov 13, 2019

BUY
$59.06 - $72.15 $3.41 Million - $4.16 Million
57,700 Added 3.29%
1,813,011 $109 Million
Q2 2019

Aug 12, 2019

BUY
$62.09 - $86.14 $109 Million - $151 Million
1,755,311 New
1,755,311 $113 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.12B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.